Picture loading failed.

Anti-CD3E therapeutic antibody (Pre-made Foralumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Foralumab is a fully human monoclonal antibody that binds to CD3 epsilon. Also called TZLS-401, it is currently in clinical development by Tiziana Life Sciences for treatment of Crohn's disease and other autoimmune diseases.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-220-1mg 1mg 3090
GMP-Bios-ab-220-10mg 10mg 21890
GMP-Bios-ab-220-100mg 100mg 148000
GMP-Bios-ab-220-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD3E therapeutic antibody (Pre-made Foralumab biosimilar,Whole mAb)
INN Name Foralumab
TargetCD3E
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesMedarex;NovImmune SA;Harvard Medical School;Tiziana Life Sciences
Conditions Approvedna
Conditions ActiveCrohn's disease;Neurodegenerative disorders;Primary biliary cirrhosis;Inflammatory bowel diseases;Non-alcoholic steatohepatitis;Type 2 diabetes mellitus
Conditions DiscontinuedTransplant rejection;Type 1 diabetes mellitus
Development Techna